FDA 21 CFR 211.110 Draft Guidance: Strengthening Drug Product Integrity Through In-Process Controls And Advanced Manufacturing

Ensuring drug product integrity, batch uniformity, and consistent pharmaceutical quality remains a core expectation under the U.S. Food and Drug Administration’s Current Good Manufacturing Practice (CGMP) framework. As manufacturing technologies continue evolving, the FDA has released draft guidance titled:

21 CFR 211.110

This draft provides important clarification regarding:

• In-process controls 
• Process monitoring expectations 
• Advanced manufacturing technologies 
• Process Analytical Technology (PAT) 
• Continuous manufacturing systems 
• Risk-based quality management 
• Real-time process verification 

The guidance reflects the FDA’s broader push toward modern pharmaceutical manufacturing systems that improve product quality, manufacturing robustness, and supply chain resilience.

For pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and quality leaders, understanding the FDA’s expectations under 21 CFR 211.110 is becoming increasingly important for maintaining inspection readiness and long-term CGMP compliance.

This detailed guide by Maven Regulatory Solutions explains the regulatory expectations, advanced manufacturing implications, compliance strategies, and operational impact of the FDA’s 21 CFR 211.110 draft guidance.

Regulatory Context: Understanding 21 CFR 211.110

21 CFR 211.110

establishes FDA requirements for in-process controls and testing during drug manufacturing operations.

The regulation reinforces a fundamental pharmaceutical quality principle:

Quality cannot be tested into a product it must be built into the manufacturing process.

The guidance emphasizes maintaining process control throughout the manufacturing lifecycle to ensure finished drug products consistently meet predefined quality attributes.

Applicability of 21 CFR 211.110

The regulation applies broadly to:

• Human drug products 
• Animal drug products 
• Biological drug products 

Not Applicable To

• Active Pharmaceutical Ingredients (APIs) 

Although APIs remain subject to separate GMP frameworks, finished dosage manufacturing operations fall directly within the scope of this regulation.

Core FDA Expectations Under 21 CFR 211.110

The draft guidance expands on several key CGMP expectations.

FDA Focus Areas

The FDA continues emphasizing science-based and risk-driven manufacturing controls.

Understanding In-Process Controls

In-process controls are operational checks performed during manufacturing to monitor and adjust process performance before final product release.

Purpose of In-Process Controls

• Maintain batch uniformity 
• Detect process variability 
• Preventing deviations 
• Support validated process performance 
• Protect product quality and patient safety 

These controls form a central pillar of modern pharmaceutical quality systems.

Advanced Manufacturing: FDA’s Forward-Looking Approach

The guidance strongly encourages adoption of advanced pharmaceutical manufacturing technologies.

Examples of Advanced Manufacturing Technologies

• Continuous manufacturing 
• Additive manufacturing (3D printing) 
• Process Analytical Technology (PAT) 
• Real-time release testing (RTRT) 
• Automated feedback control systems 
• Predictive process monitoring 

The FDA views these technologies as important tools for improving:

• Process robustness 
• Manufacturing efficiency 
• Product consistency 
• Supply chain reliability 

FDA’s Support for Pharmaceutical Innovation

The FDA continues supporting advanced manufacturing through programs such as:

Emerging Technology Team (ETT)

and

Advanced Technologies Team (ATT)

These programs encourage early engagement between industry and the FDA to facilitate innovation while maintaining CGMP compliance.

Process Analytical Technology (PAT) and Real-Time Monitoring

Modern manufacturing systems increasingly rely on:

Process Analytical Technology

to monitor critical process parameters and quality attributes in real time.

Benefits of PAT

PAT shifts quality oversight from end-product testing toward continuous process verification.

Real-Time Release Testing (RTRT)

The guidance also supports:

Real-Time Release Testing

where product quality is assured through process controls and monitoring rather than relying exclusively on finished-product testing.

Potential Advantages of RTRT

• Faster batch release 
• Reduced laboratory burden 
• Improved manufacturing efficiency 
• Enhanced process confidence 

RTRT implementation requires strong validation and scientific justification.

Role of Process Models in Modern Manufacturing

Process models are increasingly used to support manufacturing decisions and process control.

Types of Process Models

• Statistical models 
• Mechanistic models 
• Hybrid predictive models 

These models may support:

• Process optimization 
• Predictive monitoring 
• Continuous manufacturing control 
• Real-time decision-making 

FDA’s Position on Process Models

The FDA acknowledges the benefits of process models but emphasizes that they cannot operate without oversight.

FDA Recommendation

Process models should be supported by:

• In-process testing 
• Monitoring systems 
• Continuous verification activities 

This ensures ongoing CGMP compliance and model reliability.

In-Process Sampling & Testing Expectations

Guidance allows flexibility in sampling approaches when scientifically justified.

FDA-Accepted Sampling Approaches

• At-line testing 
• On-line testing 
• In-line testing 
• Traditional off-line testing 

Manufacturers are expected to justify:

• Sampling locations 
• Sampling frequency 
• Testing methodologies 
• Monitoring strategies 

based on process understanding and risk evaluation.

Maintaining a “State of Control”

A recurring theme throughout the guidance is maintaining a:

State of Control

A state of control exists when manufacturing processes consistently produce products meeting predefined quality standards.

Key Elements of State of Control

• Ongoing process verification 
• Continuous monitoring of CQAs 
• Trend analysis 
• Change management 
• Variability control 
• Lifecycle process management 

Maintaining a validated state of control remains central to FDA inspection expectations.

Lifecycle Process Validation & Continuous Verification

The FDA continues to emphasize lifecycle-based validation approaches rather than one-time validation activities.

Lifecycle Validation Focus Areas

Continuous process verification supports sustainable compliance throughout product lifecycles.

Data Integrity Expectations

The FDA expects all in-process monitoring systems to comply with robust data integrity principles.

Key Data Integrity Expectations

• Accurate recording 
• Complete traceability 
• Secure electronic systems 
• Audit trail functionality 
• Controlled access management 
• Reliable documentation practices 

Data integrity failures remain a major source of FDA inspection observations.

Practical Impact for Pharmaceutical Manufacturers

The draft guidance has significant implications across manufacturing operations.

Affected Operational Areas

• Process design 
• Process validation 
• Manufacturing controls 
• Technology transfer 
• Lifecycle management 
• Inspection readiness 
• Pharmaceutical Quality Systems (PQS) 

Potential Compliance Benefits

Organizations adopting proactive control strategies may gain both regulatory and operational advantages.

Inspection & Regulatory Considerations

FDA investigators may increasingly evaluate:

• Process understanding 
• Real-time monitoring controls 
• PAT implementation 
• Model validation 
• Lifecycle verification systems 
• Data integrity practices 

Inspection expectations continue shifting toward science-based manufacturing oversight.

Future Trends in Pharmaceutical Manufacturing Regulation

Several regulatory trends are shaping the future of pharmaceutical manufacturing.

Emerging Trends

• Expanded continuous manufacturing adoption 
• Greater use of AI-assisted process analytics 
• Increased digital manufacturing oversight 
• Enhanced predictive quality systems 
• More real-time release testing frameworks 
• Stronger lifecycle management expectations 

The pharmaceutical industry continues moving toward data-driven manufacturing environments.

Quick Facts

• 21 CFR 211.110 governs in-process controls during drug manufacturing 
• FDA supports advanced manufacturing technologies 
• PAT and RTRT are increasingly encouraged 
• Process models require ongoing verification 
• Continuous process monitoring is essential 
• Lifecycle validation remains a regulatory priority 
• Data integrity expectations continue expanding 

Why This Guidance Matters

Organizations failing to modernize manufacturing controls may face:

• FDA inspection observations 
• Increased process deviations 
• Batch inconsistency risks 
• Validation gaps 
• Data integrity concerns 
• Reduced manufacturing efficiency 

Proactive alignment with FDA expectations improves long-term compliance sustainability.

How Maven Regulatory Solutions Supports FDA 21 CFR 211.110 Compliance

Our Services

• In-process control strategy development 
• CGMP gap assessments 
• Advanced manufacturing readiness support 
• PAT and RTRT implementation alignment 
• Lifecycle validation consulting 
• FDA inspection readiness support 
• Process monitoring strategy development 
• Pharmaceutical Quality System optimization 

Why Choose Maven

• Deep FDA regulatory expertise 
• Science-based compliance strategies 
• Strong manufacturing compliance capabilities 
• Inspection-focused consulting approach 
• Up-to-date advanced manufacturing knowledge 
• Lifecycle-oriented regulatory support 

Learn more at Maven Regulatory Solutions

Preparing for FDA Advanced Manufacturing & In-Process Control Compliance?

Whether you are implementing PAT systems, strengthening lifecycle validation programs, modernizing in-process controls, or preparing for FDA inspections, Maven Regulatory Solutions can help align your operations with evolving FDA expectations.

Contact Maven Regulatory Solutions For:

• FDA CGMP compliance consulting 
• In-process control strategy support 
• PAT and RTRT regulatory alignment 
• Lifecycle validation planning 
• Advanced manufacturing readiness 
• FDA inspection preparation 
• Pharmaceutical quality systems support 

Visit Maven Regulatory Solutions to connect with our pharmaceutical manufacturing compliance experts.

Conclusion

The FDA’s draft guidance on 21 CFR 211.110 reinforces a modern, science-driven approach to pharmaceutical manufacturing quality, process control, and lifecycle compliance.

By integrating robust in-process controls, advanced monitoring systems, and continuous verification strategies, pharmaceutical manufacturers can improve product integrity, operational efficiency, and regulatory confidence.

As manufacturing technologies continue evolving, organizations adopting proactive, risk-based quality systems will be better positioned for long-term compliance and supply chain resilience in an increasingly data-driven pharmaceutical environment.

Frequently Asked Questions

Q1. Is the FDA draft guidance legally binding?

No. Draft guidance represents the FDA’s current thinking and expectations but does not establish legally enforceable obligations beyond existing regulations.

Q2. Does the guidance replace existing CGMP requirements?

No. It clarifies FDA’s interpretation of existing CGMP expectations under 21 CFR 211.110.

Q3. Can process models replace in-process testing?

Not entirely. The FDA expects process models to be supported by appropriate monitoring and verification systems.

Q4. Is continuous manufacturing encouraged by the FDA?

Yes. The FDA strongly supports advanced manufacturing technologies when implemented with appropriate controls.

Q5. Does this apply to legacy pharmaceutical products?

Yes. Lifecycle process verification expectations apply across product lifecycles, including established products.

Q6. What is the purpose of maintaining a state of control?

A state of control ensures manufacturing processes consistently produce products meeting predefined quality requirements.

Q7. How can Maven help with 21 CFR 211.110 compliance?

Maven supports control strategy development, PAT alignment, lifecycle validation, inspection readiness, and advanced manufacturing compliance initiatives.